METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo targets genetic weakness in advanced prostate cancer
Disease control OngoingThis phase 3 study tests whether adding niraparib to standard therapy (abiraterone acetate plus prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer that has certain gene mutations (HRR). About 696 participants received either the combo o…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
Could smarter dosing delay resistance in prostate cancer?
Disease control OngoingThis study tests whether giving hormone therapy and chemotherapy in an adaptive, on-and-off pattern can keep advanced prostate cancer sensitive to treatment longer. About 25 men with stage IV prostate cancer that still responds to hormones will receive this approach. The goal is …
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 19, 2026 12:01 UTC